Effects of plasmid-mediated growth hormone releasing hormone supplementation in young, healthy Beagle dogs1
- 1 September 2003
- journal article
- research article
- Published by Oxford University Press (OUP) in Journal of Animal Science
- Vol. 81 (9) , 2301-2310
- https://doi.org/10.2527/2003.8192301x
Abstract
Our study focused on the evaluation of the pharmacological and toxicological effects of plasmid-mediated GHRH supplementation with electroporation in normal adult dogs over a 180-d period. Twenty-eight dogs (P < 0.001), without organomegaly. Serum glucose and insulin in fasted dogs remained within normal ranges at all time points. Adrenocorticotropic hormone was normal in all groups. Significant increases in number of red blood cells, hematocrit, and hemoglobin (P < 0.01) were observed. In conclusion, our study shows that plasmid-mediated GHRH supplementation is safe in electroporated doses up to 1.0 mg in young healthy dogs.Keywords
This publication has 45 references indexed in Scilit:
- Enhanced animal growth via ligand regulated GHRH myogenic injectable vectorsThe FASEB Journal, 2002
- Gene Therapy for the Treatment of Hemophilia B Using PINC-Formulated Plasmid Delivered to Muscle with ElectroporationMolecular Therapy, 2001
- Growth hormone: current and future therapeutic applicationsExpert Opinion on Pharmacotherapy, 2000
- Treatment of cachexia with recombinant growth hormone in a patient before lung transplantationCritical Care Medicine, 1999
- Effect of Chronic Growth Hormone Administration on Skeletal Muscle in DogsToxicologic Pathology, 1998
- Pharmacological and Toxicological Effects of Chronic Porcine Growth Hormone Administration in DogsToxicologic Pathology, 1998
- Assessment of Red Blood Cell Indices in Growth-Hormone-Treated ChildrenHormone Research, 1997
- Growth Hormone Response Induced by Synthetic Human Growth Hormone‐Releasing Factor (1–44) in Healthy DogsJournal of Veterinary Medicine Series A, 1989
- Pulsatile growth hormone secretion in normal man during a continuous 24-hour infusion of human growth hormone releasing factor (1-40). Evidence for intermittent somatostatin secretion.Journal of Clinical Investigation, 1985
- characterization of A 40 residue peptide from a human pancreatic tumor with growth hormone releasing activityBiochemical and Biophysical Research Communications, 1982